Proud that our chemoproteomics survey is out @ Science Magazine . Proteome-wide profiling of >400 fragments coupled with AI/ML provides numerous starting points for drug discovery & empowers prediction of ligand behavior in native biological systems.
science.org/doi/10.1126/sc…

Interested in developing degrader drugs that could save lives of kids with cancer? Look no further. We are recruiting 4 scientists at Centre for Targeted Protein Degradation to do just that as part of our Cancer Grand Challenges #CancerGrandChallenges KOODAC team. Role 1/4: Senior Lead Scientist nature.com/naturecareers/…

We’re looking forward to the Biophysics for Drug Discovery Summit this week where Dipti Saldage and Asad Taherboy will be presenting! Download the agenda for details on their presentations: bit.ly/3w5cwY5

So much fun putting together this special Symposium with Valentina Spiteri , Alessio Ciulli, Craig Crews, Brenda and team.

Only 1 month to go! #TPDFocus

Super happy to receive this award 🎉! Huge thanks to my wonderful group, the selection committee and the supportive environment
EFMC NCCR Catalysis ZHAW

Looking forward to presenting our science at the EFMC-ISMC conference in Rome!

efmc.info/prizes

Measuring Ligand-bound Protein Complexes with Proximity Labeling: A Practical Guide (J. G. English, F. M. Ferguson et al.) Fleur Ferguson onlinelibrary.wiley.com/doi/10.1002/cb…

Excellent work Fleur Ferguson !

We're pleased to welcome Kristian Humer as Chief Financial Officer of Foghorn! With deep experience from both the life science industry and finance, we look forward to leveraging his expertise: bit.ly/4ayPV5m

#FlagshipFounded Foghorn Therapeutics presents new preclinical data on potential first-in-class BRM selective inhibitor FHD-909 and selective CBP and selective EP300 degrader oncology programs.

At #AACR24 , in collaboration with Foghorn Therapeutics, we’re excited to share the first presentation of preclinical data for an oral BRM (SMARCA2) selective inhibitor.

See the analysis here: e.lilly/3PGkyxo

#CancerResearch #PrecisionMedicine #SMARCA2

Love it! ❤️

Hanging out with the incredible Ines Forrest! Women in TPD & Induced Proximity

I continue my exceptional selfie photos! Dan Nomura Alex Waterson Keith Hornberger #aacr24

I did it! Selfie with Ingo Hartung and Keith Hornberger together in one photo! #AACR24 #CICR #chemicalbiologists ☺️

Enjoying the scenic California coast with my amazing Foghorn Therapeutics colleagues! 🚲
Cannot wait for the opening Plenary and New Drugs on the Horizon talks today! #AACR24

This evening, the 30 members of the 2024 class of AACR Fellows were inducted into the AACR Academy. The distinguished scientists who comprise the AACR Academy serve as a global brain trust, providing scientific leadership to advance the AACR's mission. #AACR24

My colleague Marcel Rieker Merck about bringing together two exciting areas of drug discovery: protein degraders & antibody-drug conjugates. Delivering degraders to diseased cells in (very) complicated ways and in potentially more simple ones. #TPD #ADC #AACR24

We congratulate the 2024 Class of Fellows of the AACR Academy. The newest AACR Fellows will be inducted during a special ceremony on Friday, April 5 at #AACR24 . bit.ly/3xiyB5H

Join us at Cambridge Healthtech Institute’s 7th Annual Degraders & Molecular Glues Meeting for a presentation on our selective CBP and selective EP300 programs to learn about our progress in optimizing these degraders. See the program: bit.ly/43EJkUg

Just in time for #HumpDay : Our study Targeting DCAF5 suppresses #SMARCB1 -mutant #cancer via stabilizing SWI/SNF is online now in nature. Congratulations 🎉 to co-first authors Sandi-Radko-Juettner and Hong Yue and all co-authors on this story! 1/
nature.com/articles/s4158…